PoA = probability-of-approval band (directional only; not FDA guidance).
Rule: FDA decision events get a %; data/KOL/conference events get N/A.
THE FRAME (MAR 20–MAR 27): “RYTM PDUFA DECISION → CONFERENCE DATA PRINTS → NEXT WEEK’S FDA CLOCKS”
Last Friday’s setup was ALDX + RLAY + ANVS data prints. That tape has now largely printed:
ALDX received a Complete Response Letter on Mar 17. FDA cited lack of substantial evidence of efficacy in adequate and well-controlled studies, inconsistent results across trials, and concerns about reliability of positive findings. No new safety or CMC issues were flagged.
RLAY delivered clean Phase 1/2 data at ESMO TAT on Mar 16 for zovegalisib (400 mg BID fed, the Phase 3 dose) + fulvestrant in PI3Kα-mutated HR+/HER2– metastatic breast cancer. Median PFS 11.1 months and ORR 43% support the ReDiscover-2 setup.
CRVO / ABOS presentations at AD/PD 2026 continue to reinforce prior signals: CRVO = CervoMed / neflamapimod in DLB, while ABOS = Acumen / sabirnetug biomarker and brain-delivery work.
LNTH PDUFA for LNTH-2501 was extended three months to June 29, 2026 for additional review time.
So the tape now narrows to:
IMMEDIATE VISIBILITY / TRADEABLE WINDOWS (NEXT ~7 DAYS)
RYTM — $RYTM ( ▲ 1.05% ) | IMCIVREE® (setmelanotide) | PDUFA: Fri Mar 20 | PoA: 78%
Next hard FDA clock. Rhythm announced additional positive TRANSCEND data on Mar 1 and said it would submit the final data package to FDA on Mar 2, 2026. Breakthrough Therapy Designation and prior obesity-label experience continue to de-risk the setup. Safety remains consistent with prior experience.
What will trade:
whether FDA treats the added analyses and expanded dataset as confirmatory rather than noise
any labeling / PMR language around hunger scores or durability
post-decision launch commentary and commercial-readiness tone
QUICK CALENDAR (MAR 20–MAR 27)
Day | Ticker | Event | Why it matters |
|---|---|---|---|
Fri Mar 20 | RYTM | PDUFA (AHO) | next clean FDA decision |
Sat Mar 21 | ABOS | AD/PD oral + posters | mechanism / biomarker support for ALTITUDE-AD |
Mon Mar 23 | OCS | NANOS 2026 presentation (Privosegtor ACUITY Phase 2) | LCVA + neuroprotective structural data |
Mon–Tue Mar 23–24 | TELO | World Congress Breast Cancer | TNBC preclinical xenograft data |
Tue Mar 24 | GSK | PDUFA — linerixibat (PBC) | next hard FDA clock after RYTM |
Thu Mar 26 | MDCX | Business update webcast (SkinJect Phase 2) | clinical vs histological clearance interpretation |
WHAT WE MISSED / WHAT CHANGED
$LNTH ( ▼ 1.31% ) PDUFA is now June 29.
$ALDX ( ▲ 3.83% ) moved from live binary to third CRL.
$RLAY ( ▼ 0.3% ) printed cleaner-than-feared at the exact Phase 3 dose.
$GSK ( ▼ 1.03% ) linerixibat (Mar 24) is the next hard FDA clock after RYTM.
CLOSING NOTE
This week was about resolution. ALDX closed one chapter. RLAY and AD/PD prints kept momentum alive in oncology and neuro. The actionable shift is:
$RYTM ( ▲ 1.05% ) is the immediate hard FDA clock today
$GSK ( ▼ 1.03% ) becomes the next hard FDA clock on Tue Mar 24
$RCKT ( ▲ 0.91% ) remains the key month-end FDA event on Mar 28
$LNTH ( ▼ 1.31% ) has been pushed out cleanly to late June.
Disclaimer: informational only; not investment advice; biotech carries risk of total loss